KR100494871B1 - Extracts of CHAGA mushroom showing antioxidant and lipid metabolic activity, the extraction method and the use thereof - Google Patents

Abstract

The present invention relates to a chaga mushroom extract having an antioxidant effect and an effect on lipid metabolism and a method of extracting the chaga mushroom extract of the present invention by adding chaga to about 10 times the amount of water and autoclaving at 100 ° C. for 4 hours. After extracting by autoclaving, the supernatant obtained by centrifugation of the extract was purified, and the extract according to the present method was obtained by increasing the antioxidant activity and free radicals involved in inhibiting various adult diseases and further aging due to the decrease in blood lipid concentration. It provides an excellent effect on the reduction of the present invention to provide health supplements and medicines effective in the prevention and treatment of geriatric diseases such as atherosclerosis.

Description

Extract of Chaga mushroom showing antioxidant and lipid metabolic activity, the extraction method and the use}

The present invention relates to a method of using antioxidant chaga and natural metabolism, and a method for improving lipid metabolism.

Since all aerobic organisms inevitably carry harmful free radical species during metabolism, all organisms must have a mechanism to remove these free radical species in order to survive. Active oxygen species can be broadly classified into two types: compounds that form oxygen radical species, such as hydrogen peroxide, and oxygen radical species. As already known, the hydrogen peroxide is catalase (catalase) or the case of peroxidase (peroxidase) oxygen, but the conversion of water, oxygen radical species are removed by the mechanism, O ₂ ^- other oxygen radicals other than the mechanism of removing (superoxide anion) Species removal mechanisms are not yet clear.

Hydroxy radicals, a type of oxygen radical species, are formed by the reaction of H ₂ O ₂ and O ₂ in living things and are known to be present in almost all biomolecules [Fridovich et al., Ann. Rev. Biochem ., 44 , pp 147-159, 1975; Tauber et al., Blood , 53, pp 666-676, 1979]. Therefore, it is obvious that defense against highly reactive hydroxy radicals is required in order to maintain homeostasis in vivo. In this respect, organic materials such as ascorbic acid and uric acid are known to remove hydroxy radicals by chemical reaction, but this is not fundamentally to remove hydroxy radicals but to convert them into less reactive radicals, as well as oxidizing agents in vivo. It has been reported that it can react with a transition metal such as iron to promote the production of reactive oxygen radical species [Borg, DC and Schaich, KM, Handbook of Free Radicals and Antioxidant in Biomedicine, Vol. I, pp 63-80, CRC press, 1989].

Physiological processes radicals generated during ^{_{(O 2 -, H 2 O}} 2, OH and O ₂₎ is a free radical reaction in which a very strong reactivity caused by these represents the destruction effect of major macromolecules, including lipids [Davies , KJA and Goldberg, AL, J. Biol. Chem., 262 , p8220-8226, 1987]. Their production is increased by a number of factors that cause abnormal metabolic processes, photosensitization, drug metabolism, and other cellular metabolism, and therefore, living organisms are always exposed to the harmful effects of free radical reactions caused by them. Morehouse, LA and Thomas, CE, J. Free Radicals Biol. Med., 1, p 8, 1985]. In particular, if cells continue to accumulate harmful effects due to their harmful radicals as they age, they cause aging of the cells as well as diseases related to various adult diseases such as carcinogenesis, arteriosclerosis, heart disease, and skin aging. It has been suggested as a cause of human disease occurrence and aging [Harman, D., Free Radicals in Biology , Academic Press, New York, pp 255-275 1982]. Therefore, by inhibiting free radical reactions in vivo by reactive oxygen metabolites or removing harmful free radicals accumulated in the human body, candidates are expected to be useful for the treatment of diseases such as lipid metabolism, immune diseases and cancer. Research has continued. Lipids are indispensable nutrients that must be ingested in order to maintain the life of a living body and participate in various metabolic activities of life phenomena. That is, lipids, firstly, play a role in the heat energy source of the living body to maintain a continuous supply of calories, and secondly, supply components of body components that are replaced as part of the ongoing metabolism, and thirdly, control various kinds of metabolism required for metabolism. It is responsible for constructing the arguments. Lipids as an energy source contain a high calorie value of 9 cal per gram, which is an efficient energy storage form. Essential fatty acids, which are essential components of phospholipids, are components of cell membranes of all biological tissues, and thus all substances that participate in metabolic activity. Because of the passage of lipids, the lipids are involved in the metabolism and regulation of life. In addition, cholesterol, which is a type of lipid, becomes a material of corticosteroids and sex hormone biosynthesis, which are assimilation hormones produced by the adrenal glands. These hormones all have a common structure, commonly called steroid hormones, and are responsible for regulating metabolism in the body, especially for maintaining homeostasis. Lipids are an important component of body tissue cells and their metabolic abnormalities are involved in the pathogenesis of many diseases. In particular, arteriosclerosis is well known as the most frequent disease caused by abnormal lipid metabolism. Arteriosclerosis is recognized as the main pathogenesis of large vessel disease, namely angina pectoris, myocardial infarction, and cerebral hemorrhage, which has recently been pointed out as a problem in Korea It is becoming. It is well known that major risk factors related to the development of macrovascular disease are hypertension, smoking, and diabetes, including lipid metabolism disorder. Among these risk factors, hypertension has been pointed out to be a cause of atherosclerosis and a disease caused by atherosclerosis.

Chaga has already been widely used as a medicinal cure in the Kamchatka Peninsula in the Far East, the Northern Hemisphere of Japan, Mongolia, and the volcanic region of the altitude of 45 degrees north latitude. It is written that this is a widely known background. Therefore, this chaga is a parasitic mushroom that grows on the birch and is called 'chaga' in Russia and 'cabano-anatake' in Japan, and it has begun artificial culture of chaga by cultivating strains. Is said to be in progress. Already, natural chaga is recognized as a raw material for food as the Food and Drug Administration has proved its stability in food and medicine. As this fact became known, many researchers in Japan, Europe and the United States became interested in the preparation of chaga.

The present inventors focused on finding the antioxidant effect and the effect on lipid metabolism from chaga, and as a result, the present invention was completed by confirming the antioxidant and lipid metabolism of chaga.

It is an object of the present invention to provide an extract effective for the treatment of antioxidant activity and lipid metabolism disease.

The present invention also provides a method of preparing the extract.

It is also an object of the present invention to provide a pharmaceutical composition and health supplements effective for the prevention and treatment of antioxidant activity and lipid metabolism diseases.

In order to accomplish the above object, the present invention provides chaga extract effective in the treatment of antioxidant activity and lipid metabolism disease.

The chaga extract is extracted from mushrooms selected from artificially cultivated or wild mushrooms of the genus Fuscoporia oblquus , Fuscoporia punctata and Inonotus obliquus . Containing extracts.

The chaga extract includes all of the extract extracted from the surface portion and flesh portion of the mushroom.

In addition, the present invention provides a method for producing the chaga extract.

In more detail, the present invention,

(a) about 1 to 1000 times the volume of natural chaga mushroom weight, preferably about 10 to 100 times the volume of water, and then 20 to 300 ℃, preferably 60 to 200 ℃ 1 minute to 10 days, A first step of performing extraction by autoclaving, reflux cooling extraction, preferably extraction by autoclaving, preferably with stirring for 12 hours to 3 days,

(b) a second step of centrifuging the extract to recover only the precipitate and re-extracting according to the first step;

(c) suspending the precipitate by adding a volume of about 1 to 1000 times by weight, preferably about 10 to 100 times by weight of methanol, ethanol, butanol and the like and a lower alcohol, preferably ethanol, and centrifuging the suspension. A third step of concentrating the obtained supernatant under reduced pressure,

(d) provides a method for extracting chaga extract comprising the fourth step of purifying by adding the same amount of an organic solvent, preferably ethanol to the concentrate.

In another aspect, the present invention provides an antioxidant and a pharmaceutical composition for treating lipid metabolism diseases containing chaga mushroom extract prepared by the above method as an active ingredient.

Lipid metabolic diseases of the present invention include diseases such as hypertension, arteriosclerosis, angina pectoris, cerebral hemorrhage, myocardial infarction and the like caused by increased cholesterol in the blood.

The composition comprising the mushroom extract of the present invention of the present invention may further comprise suitable carriers, excipients and diluents commonly used in the manufacture of pharmaceutical compositions.

As a means of preventing the disease and anti-aging effect of adult diseases, chaga mushroom extracts were tested for antioxidant capacity by hot water and cold water extraction in vitro. As a result, cold water extraction did not have antioxidant capacity, whereas hot water extraction showed antioxidant activity. Excellent results were obtained. In addition, animal experiments administered to SD rats (Sprague-Dawley rats) showed that not only can significantly inhibit the neutral lipids and LDL-cholesterol known as the cause of adult disease, but also the amount of HDL-cholesterol that inhibits adult disease. Increased effectively. In addition, the inhibitory effect of the adult disease was recognized by effectively inhibiting the atherosclerotic index (AI), which is used as an indicator of atherosclerosis, which is an early symptom of adult disease. In addition, super oxide radical (O ₂ to facilitate ^age-, hydroxy radicals (· OH) lipid peroxide (lipid peroxide produced by not only inhibiting the generation of free radicals, such as effectively to attack by reactive oxygen species: LPO) In addition, the activity of superoxide dismutase (SOD) as an active oxygen scavenger was also effectively increased, indicating that the inhibitory effect of aging was remarkable.

 The composition comprising the extract of the present invention may further comprise a suitable carrier, excipient and diluent according to conventional methods.

Carriers, excipients and diluents that may be included in the composition comprising the extract of the present invention include lactose, dextrose, sucrose, sorbitol, mannitol, xylitol, erythritol, maltitol, starch, acacia rubber, alginate, gelatin, calcium Phosphate, calcium silicate, cellulose, methyl cellulose, microcrystalline cellulose, polyvinyl pyrrolidone, water, methylhydroxybenzoate, propylhydroxybenzoate, talc, magnesium stearate and mineral oil.

Compositions comprising extracts according to the invention are formulated in the form of powders, granules, tablets, capsules, suspensions, emulsions, syrups, aerosols and the like, oral preparations, suppositories and sterile injectable solutions, respectively, according to conventional methods. Can be used.

The amount of the extract of the present invention may vary depending on the age, sex, and weight of the patient, but may be administered once to several times in an amount of 0.1 to 100 mg / kg. In addition, the dosage of the extract can be increased or decreased depending on the route of administration, the degree of disease, sex, weight, age and the like. Therefore, the above dosage does not limit the scope of the present invention in any aspect.

In addition, chaga extract of the present invention can be used as a main, secondary ingredients and food additives of other foods.

In another aspect, the present invention provides a dietary supplement comprising chaga extract and food acceptable food additives for preventing adult diseases.

The composition comprising the extract of the present invention can be used in various ways, such as drugs, foods and drinks for the prevention and treatment of lipid metabolism diseases. Examples of the food to which the extract can be added include various foods, beverages, gums, teas, vitamin complexes, and health supplements.

Extract itself of the present invention is a drug that can be used with confidence even for long-term administration for the purpose of prevention because there is little toxicity and side effects.

The extract of the present invention may be added to food or beverage for the purpose of prevention of lipid metabolism disease. At this time, the amount of the extract in the food or beverage is generally added to the health food composition of the present invention 0.01 to 15% by weight of the total food weight, the health beverage composition is 0.02 to 10 g based on 100 ml, preferably Can be added in a ratio of 0.3 to 1 g.

The health beverage composition of the present invention has no particular limitations on the liquid component except for containing the extract as an essential ingredient in the indicated ratio, and may contain various flavors or natural carbohydrates as additional ingredients, such as ordinary drinks. Examples of the above-mentioned natural carbohydrates include monosaccharides such as glucose, fructose and the like; Disaccharides such as maltose, sucrose and the like; And conventional sugars such as polysaccharides such as dextrin, cyclodextrin, and sugar alcohols such as xylitol, sorbitol, and erythritol. As flavoring agents other than those mentioned above, natural flavoring agents (tauumatin, stevia extract (for example, rebaudioside A, glycyrrhizin, etc.) and synthetic flavoring agents (saccharin, aspartame, etc.) can be advantageously used. The proportion of said natural carbohydrates is generally about 1-20 g, preferably about 5-12 g per 100 ml of the composition of the present invention.

In addition to the above, the composition of the present invention includes various nutrients, vitamins, minerals (electrolytes), flavors such as synthetic flavors and natural flavors, coloring and neutralizing agents (such as cheese and chocolate), pectic acid and salts thereof, alginic acid and salts thereof. , Organic acids, protective colloidal thickeners, pH adjusters, stabilizers, preservatives, glycerin, alcohols, carbonation agents used in carbonated beverages, and the like. The compositions of the present invention may also contain pulp for the production of natural fruit juices and fruit juice beverages and vegetable beverages. These components can be used independently or in combination. The proportion of such additives is not so critical but is generally selected from the range of 0 to about 20 parts by weight per 100 parts by weight of the composition of the present invention.

The present invention is described in more detail based on the following examples, although the present invention is not limited thereto.

Example 1. Preparation of chaga hot water extract (1)

1 kg of dried chaga mushrooms from Siberia and China were selected and the birch bark was removed, and the coal-shaped surface (black) was separated and chopped, and then 10 liters of purified water was added and 4 hours at 100 ° C. The mixture was extracted by autoclaving with stirring, and the extracted extract was centrifuged to recover the precipitate and the obtained supernatant, which was used as a sample.

Example 2. Preparation of Chaga Hot Water Extract (2)

1 kg of dried chaga mushrooms from Siberia and China were selected and the birch bark was removed, and the contents of chaga, ie, flesh parts (yellow), were separated and chopped, and then 10 liters of purified water was added at 100 ° C. The mixture was extracted by autoclaving with stirring for 4 hours, the extracted extract was centrifuged to recover the precipitate and the obtained supernatant, and the supernatant was used as a sample.

Comparative Example 1. Preparation of chaga cold water extract (1)

1 kg of dried chaga mushrooms from Siberia and China were carefully selected to remove the bark of the birch, and the coal-shaped surface (black) was separated and shredded separately. 10 liters of purified water was added for 4 hours at room temperature. The mixture was extracted by autoclaving with stirring, the extracted extract was centrifuged to recover the precipitate and the obtained supernatant, and the supernatant was used as a sample.

Comparative Example 2. Preparation of Chaga Mushroom Cold Water Extract (2)

Select 1 kg of dried chaga mushrooms from Siberia and China, remove the birch bark, separate the contents of chaga, ie, flesh parts (yellow), and then chop each, and add 10 liters of purified water and 4 at room temperature. The mixture was extracted by autoclaving with stirring for a time, the extracted extract was centrifuged to recover the precipitate and the obtained supernatant, and the supernatant was used as a sample.

Experimental Example 1. Antioxidant efficacy test

In vitro and animal experiments were performed as follows to confirm the antioxidant efficacy of the mushroom extracts of the present invention.

In vitro experiment

In vitro experiment ( in vitro ) to verify the effect of antioxidant efficacy was verified the antioxidant capacity of the extract by the color development by DPPH method [Yoshida, T., Chem. Pharm. Bull., 37 (7), pp 1919-1921, 1989].

As a result of measuring the effect of chaga on the antioxidant capacity of the well-known vitamin C as a control group, chaga mushroom is excellent in antioxidant capacity when taking the filtrate obtained by hot water extraction, as shown in Table 1 The filtrate obtained by extraction proved to have little antioxidant capacity.

sample Sample concentration required to reduce antioxidant activity (50%) (㎍) Example 1 171.3 Example 2 233.0 Comparative Example 1 1226.1 Comparative Example 2 1458.5 Vitamin c 6.2

Animal experiment

In order to confirm the therapeutic efficacy of anti-aging of the mushroom extracts of the present invention, the following experiment was performed.

The experimental animals used in this animal experiment were 4 weeks old Sprague-Dawley rats (120 ± 10g ♂, Daegu Hyochang Science) for adult disease and anti-aging experiments. , The experimental group was administered to the functional chaga supernatant of the present invention instead of water and then tested for the tonic effect using blood.

The reagents used in this experiment were all first-grade or higher reagents, and related enzyme reagents were measured using sigma-express reagents.

Experiment method

(1) Collection and Separation of Blood

After anesthetizing the experimental animals with ether, blood was collected from the heart, left for 2 hours at low temperature, centrifuged at 700xg for 10 minutes, and the supernatant was treated with 0.05 ml of CBC (1.0 mL) per 1.0 ml of blood. Cell count (green cross) was used for analysis while cryopreservation at -70 ℃.

(2) Determination of free radicals and lipid peroxide (LPO)

The measurement of hydroxy radicals, known as the most powerful free radicals among free radicals, is a measure of the degree of hydroxyl radical generation to the extent of deoxyribose destruction. Ribose is destroyed to form aldehydes which are developed by reaction with thiobarbituric acid in acidic solutions. Halliwell B and Gutteridge JMC, FEBS. Lett., 128, pp347-350, 1981].

The content of lipid peroxide (LPO) in serum known to be produced by these oxygen radicals is measured as described in Choi JH and Yu BP, AGE, 13, pp 61-64, 1990. It was.

(3) Determination of activity of the eliminating enzyme

Determination of superoxide dismutase (SOD) activity, which is important as an enzyme for removing reactive oxygen species, is described in Oyanagui, Y, Anal. Biochem., 42, pp 290-296, 1984]. In addition, the activity of glutathione peroxidase (GSHPx) in serum was measured as a method for measuring the reduction of NADPH at 340 nm as an important scavenger in vivo [Lawrence, RA and Burk, RF, Lipid, 19, pp444 -452, 1978].

Haman's theory, the most widely accepted theory of aging, has been focused on promoting aging by cytotoxicity of lipid peroxide by oxidation of lipids [Harman, D. , J. Gerontol., 11, pp 298-300, 1956].

As a result of examining the effect of natural chaga on the anti-aging effect by administering the extract of the present invention to the experimental animal SD rats for 3 weeks, the production of lipid peroxide (LPO) in the chaga administration group as shown in Table 2 was compared. 19.8% of the group effectively inhibited the production of lipid peroxide. In addition, it can be seen that the effect of chaga administration on the production of hydroxy radicals, the most powerful active oxygen among free radicals, is significantly inhibited by 23.4%. In addition, when comparing the administration effect of the chaga mushroom of the present invention on the activity of superoxide dismutase (SOD) and glutathione peroxidase (GSHPx) as the active oxygen scavenging enzyme, 12.4% and 16.2%, respectively, were significant. It can be seen that the activity of SOD and GSHPx is increased. Due to the above results, it was confirmed that the administration of chaga can effectively prevent and prevent the aging process.

Item Control group Chaga Group Compared to the control group Lipid Peroxide (LPO) nmol / ml Serum 2.32 ± 0.20 1.86 ± 0.09 -19.8%  Hydroxy radical (OH) nmol / mg protein 2.99 ± 0.26 2.29 ± 0.12 -23.4% Superoxide Dismutase (SOD) unit / mg Protein 0.89 ± 0.06 1.00 ± 0.07 + 12.4% Glutathione Peroxidase (GSHPx) IU / mg Protein 46.14 ± 2.71 53.59 ± 2.94 + 16.2%

Experimental Example 2. Efficacy test on lipid metabolism

 In order to confirm the therapeutic efficacy of the lipid extracts of the mushroom extracts of the present invention, the following experiment was performed.

The experimental animals used in this animal experiment were 4 weeks old Sprague-Dawley rats (120 ± 10g ♂, Daegu Hyochang Science) for adult disease and anti-aging experiments. , The experimental group was administered to the functional chaga supernatant of the present invention instead of water and then tested for the tonic effect using blood.

Reagents used in this experiment were all first-grade or higher reagents, and related enzyme reagents were measured using Sigma Express reagent.

Experiment method

(1) odor and separation of blood

After anesthetizing the experimental animals with ether, blood was collected from the heart, left for 2 hours at low temperature, centrifuged at 700xg for 10 minutes, and the supernatant was treated with 0.05 ml of CBC (1.0 mL) per 1.0 ml of blood. Cell count (green cross) was used for analysis while cryopreservation at -70 ℃.

(2) Measurement of neutral lipids and proteins

The content of triglyceride (TG) as a triglyceride in serum was treated with TG kit reagent (Sigma, USA) for serum triglyceride measurement, and the content of triglyceride in serum was quantified based on a standard calibration curve. The content of protein in serum is described by Lowry OH, et al., J. Biol. Chem., 193, pp 265-275, 1951].

(3) determination of cholesterol content

The content of total cholesterol can be found in Rudel, LL and Morris, MD, J. Lipid. Res., 14, pp 364-366, 1973] was measured by the o -phthalaldhyde method to determine the total cholesterol content in the blood by a standard calibration curve. The contents of low density lipoprotein (LDL) and high density lipoprotein (HDL) -cholesterol in serum were measured according to the method of kit reagent (HDL-C 555, Eiken, Japan) and LDL-cholesterol (BLF, Eiken, Japan). . The atherosclerotic index (AI), which is used as an incidence index of atherosclerosis, known as an early symptom of adult disease, is the method of Haglund, O, et al., J. Nutr., 121, pp165-169, 1991 . In accordance with the following equation (1).

Atherosclerosis index (AI) = (total cholesterol-HDL cholesterol) / HDL cholesterol

The filtrate of the present invention using chaga mushroom was administered to 150g rats of SD males of experimental animals for 3 weeks to examine the effects of wild chaga on lipid metabolism. However, as shown in Table 3, the content of triglyceride and total cholesterol of the chaga-administered group was significantly suppressed by 15.8% and 16.1%, respectively. Comparing the inhibitory effect of LDL-cholesterol, which is directly related to the incidence of adult disease, the inhibitory effect was over 7.3% compared to the control group. In addition, the atherosclerotic index (AI), known as an early onset of adult disease, was significantly inhibited by 39.1% in chaga administration group. High levels of HDL-cholesterol, which is associated with exercise and longevity, also showed an increase of 11.7% in the chaga extract group, which is very effective in preventing adult diseases.

Item Control group Chaga Group Compared to the control group Neutral Lipid (TG) mg / ㎗ Serum 105.64 ± 5.79 88.96 ± 2.06 -15.8% Total Cholesterol mg / ㎗ Serum 61.50 ± 2.96 51.61 ± 4.87 -16.1% LDL-cholesterol mg / ㎗ serum 43.80 ± 2.36 40.59 ± 2.06 -7.3% HDL-cholesterol mg / ㎗ serum 22.47 ± 0.92 25.10 ± 0.71 + 11.7% Arteriosclerosis Index (AI) 1.74 ± 0.04 1.06 ± 0.05 -39.1%

Experimental Example 3. Acute Toxicity Test

1. Oral administration

 ICR-based mice and Sprague Dawley (cod hyochang science) were divided into four groups of 10 mice each, orally administered with the extracts of Example 1 of the present invention at doses of 500, 725, 1000 and 5000 mg / kg, respectively. After two weeks of toxicity, none of the four groups died and no symptoms were found.

2. Intraperitoneal administration

 ICR mice (25 ± 5 g) and Sprague Dawley (cod hyochang science) were divided into four groups of 10 mice each to extract the extract of Example 1 of the present invention 25, 250, 500 and 725 mg, respectively. Toxicity was observed for 24 hours after intraperitoneal administration at / kg. There were no deaths in all four groups and no symptoms were apparent in the control group.

From the above results, it was confirmed that the extract of the present invention has little acute toxicity.

Hereinafter, an example of the preparation of the pharmaceutical composition will be described, but it is not intended to limit the present invention but merely to explain in detail.

Formulation Example 1 Preparation of Injection

Example 1 100 mg of dry extract

Sodium Metabisulfite 3.0mg

Methylparaben 0.8mg

Propylparaben 0.1mg

Sterile distilled water for injection

The above ingredients were mixed and adjusted to 2 ml by a conventional method, and then filled into 2 ml ampoules and sterilized to prepare an injection.

Formulation Example 2 Preparation of Tablet

Example 1 200 mg of dry extract

Lactose 100mg

Starch 100mg

Magnesium Stearate

The tablets were prepared by mixing the above components and tableting according to a conventional method for producing tablets.

Formulation Example 3 Preparation of Capsule

Example 1 100 mg of dry extract

Lactose 50mg

Starch 50mg

Talc 2mg

Magnesium Stearate

 The capsules were prepared by mixing the above components and filling the gelatin capsules according to a conventional method for preparing capsules.

Formulation Example 4 Preparation of Liquid

Example 1 1000 mg of dry extract

20 g of sugar

20 g of isomerized sugar

Lemon flavor

Purified water was added to adjust the total volume to 100 ml.

The above-mentioned components were mixed according to a conventional method for preparing a liquid solution, filled into a 100 ml brown bottle, and sterilized to prepare a liquid solution.

Formulation Example 5 Preparation of Health Beverage

Example 1 0.1 to 80% of dry powder

5-10% sugar

Citric acid 0.05 ~ 0.3%

Caramel 0.005 ~ 0.02%

Vitamin C 0.1 ~ 1%

79 to 94% of purified water is mixed here to make a syrup, and the syrup is sterilized at 85 to 98 ° C. for 20 to 180 seconds, mixed with cooling water at a ratio of 1: 4, and then prepared by injecting carbon dioxide to 0.5 to 0.82%. A carbonated beverage containing mushroom dry extract was prepared.

Example 1 Homogeneous sterilization by homogeneous mixing of dry powder and subsidiary materials such as liquid fructose (0.5%), oligosaccharide (2%), sugar (2%), salt (0.5%) and water (75%) Healthy drinks were prepared by packaging in small packaging containers such as glass bottles and plastic bottles.

Although the composition ratio is a composition suitable for a preferred beverage in a preferred embodiment, the compounding ratio may be arbitrarily modified according to regional and ethnic preferences such as demand hierarchy, demand country, and use purpose.

Chaga mushroom of the present invention is a material that exists in nature and has an excellent effect as an antioxidant, lipid metabolism, immunity enhancement and anti-cancer material, so it is a very useful invention in the biopharmaceutical industry. It does not require a separate heating process and is an economical extraction method to obtain an effective extract for the prevention and treatment of antioxidant activity and lipid metabolism disease.

Claims (8)

delete delete delete delete delete delete After adding about 1 to 1000 times the volume of chaga, the mixture was stirred at 20 to 300 ° C. for 1 minute to 10 days, and the extract extracted by autoclaving was centrifuged and the supernatant was concentrated under reduced pressure. Pharmaceutical composition for the treatment of lipid metabolism disease, characterized in that hypertension, arteriosclerosis, angina pectoris, cerebral hemorrhage, myocardial infarction containing chaga extract as an active ingredient. delete